Sugi Predict

Sugi Predict / Targets / SHH

SHH

Sonic hedgehog protein · Q15465 · SHH on Sugi Atlas →

4,149 patent compounds predicted against SHH, 3,164 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Robotnikinin Robotnikinin (SCHEMBL2187337) 1.00 11/20
Robotnikinin Robotnikinin (SCHEMBL2187345) 1.00 11/20
SCHEMBL2192095 SCHEMBL2192095 0.81 11/20
SCHEMBL2192100 SCHEMBL2192100 0.81 11/20
SCHEMBL2191788 SCHEMBL2191788 0.79 11/20
SCHEMBL2191794 SCHEMBL2191794 0.79 11/20
SCHEMBL2191493 SCHEMBL2191493 0.73 10/20
SCHEMBL2191496 SCHEMBL2191496 0.73 10/20
SCHEMBL2188880 SCHEMBL2188880 0.69 9/20
SCHEMBL2188887 SCHEMBL2188887 0.69 9/20
SCHEMBL2189428 SCHEMBL2189428 0.71 8/20
SCHEMBL2189437 SCHEMBL2189437 0.71 8/20
SCHEMBL2193114 SCHEMBL2193114 0.71 8/20
SCHEMBL2193119 SCHEMBL2193119 0.71 8/20
SCHEMBL2190438 SCHEMBL2190438 0.67 8/20
SCHEMBL2190443 SCHEMBL2190443 0.67 8/20
SCHEMBL2192481 SCHEMBL2192481 0.64 8/20
SCHEMBL2192490 SCHEMBL2192490 0.64 8/20
SCHEMBL2188419 SCHEMBL2188419 0.69 7/20
SCHEMBL2188428 SCHEMBL2188428 0.69 7/20

Clinical trials — most relevant to SHH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 PHASE4COMPLETED
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer PHASE2COMPLETED
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome PHASE2WITHDRAWN
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression PHASE2COMPLETED
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) PHASE1/PHASE2WITHDRAWN
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery PHASE2COMPLETED
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma PHASE2COMPLETED
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma PHASE2COMPLETED
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer PHASE2RECRUITING
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas PHASE2COMPLETED
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma PHASE2ACTIVE_NOT_RECRUITING
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma PHASE2RECRUITING
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) PHASE2COMPLETED
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes PHASE2COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma PHASE1COMPLETED
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment PHASE1COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) PHASE1COMPLETED
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients PHASE1COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors PHASE1COMPLETED
A Study Of PF-04449913 Administered Alone In Select Solid Tumors PHASE1COMPLETED
A Study Of PF-04449913 In Select Hematologic Malignancies PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Topical Itraconazole in Treating Patients With Basal Cell Cancer EARLY_PHASE1COMPLETED
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer EARLY_PHASE1UNKNOWN
Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin. nanUNKNOWN
A Study of the Genetic Analysis of Brain Disorders nanCOMPLETED
Cancer Fusion Hybrids and Desmoplasia nanUNKNOWN
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SHH binder may also engage these)

ProteinNameSimilarity
Q63673 — 1.000 Q63673 →
Q62226 — 1.000 Q62226 →
Q14623 — 0.991 Q14623 →
Q91035 — 0.990 Q91035 →
P97812 — 0.989 P97812 →
Q61488 — 0.988 Q61488 →
Q98938 — 0.988 Q98938 →
O43323 — 0.983 O43323 →
Q90385 — 0.983 Q90385 →
Q98862 — 0.979 Q98862 →
Q91612 — 0.979 Q91612 →
Q92008 — 0.977 Q92008 →
Q92000 — 0.976 Q92000 →
P79691 — 0.975 P79691 →
Q91610 — 0.971 Q91610 →
Q91611 — 0.970 Q91611 →
Q90419 — 0.970 Q90419 →
Q9BYB0 — 0.970 Q9BYB0 →
Q8JGM4 — 0.970 Q8JGM4 →
Q8N119 — 0.969 Q8N119 →
Q6P1J0 — 0.968 Q6P1J0 →
Q9H461 — 0.968 Q9H461 →
Q8CG07 — 0.967 Q8CG07 →
Q811B1 — 0.966 Q811B1 →
Q00973 — 0.966 Q00973 →
Q09200 — 0.966 Q09200 →
Q498S8 — 0.966 Q498S8 →
Q7Z4R8 — 0.965 Q7Z4R8 →
Q9UK23 — 0.964 Q9UK23 →
Q5UCC4 — 0.964 Q5UCC4 →